Treatment of donor T cell-mediated hematopoietic suppression after haploidentical bone marrow transplantation by T cell modulation in a patient with severe combined immunodeficiency

D. Dilloo, H. Hanenberg, E. M. Schneider, M. Hauch, W. Nurnberger, B. M. Zimmer, R. Vohringer, P. Wernet, U. Gobel, S. E G Burdach

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An 8-month-old male patient with severe combined immunodeficiency syndrome was transplanted with maternal, haploidentical T cell-depleted bone marrow without prior conditioning therapy. Acute graft-versus-host disease developed 2 weeks post bone marrow transplantation (BMT) and as successfully treated with cortisone. After cortisone withdrawal the patient developed myeloid and B cell depression concomitant with T cell activation. For specific T cell modulation, treatment with the T cell receptor (TCR) αβ chain-binding MoAb BMA031 as initiated in combination with cyclosporin A. GM-CSF as given to enhance myeloid reconstitution. About 1 year post BMT, B cell and granulocyte counts were within the normal range with stable chimerism in both lineages. B cell proliferation tests were normal and first signs of in vitro immunoglobulin synthesis occurred.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalBone Marrow Transplantation
Volume9
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Severe Combined Immunodeficiency
Bone Marrow Transplantation
B-Lymphocytes
Cortisone
Tissue Donors
T-Lymphocytes
Chimerism
Behavior Therapy
Graft vs Host Disease
Myeloid Cells
Granulocyte-Macrophage Colony-Stimulating Factor
T-Cell Antigen Receptor
Granulocytes
Cyclosporine
Immunoglobulins
Reference Values
Therapeutics
Cell Count
Bone Marrow
Mothers

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Treatment of donor T cell-mediated hematopoietic suppression after haploidentical bone marrow transplantation by T cell modulation in a patient with severe combined immunodeficiency. / Dilloo, D.; Hanenberg, H.; Schneider, E. M.; Hauch, M.; Nurnberger, W.; Zimmer, B. M.; Vohringer, R.; Wernet, P.; Gobel, U.; Burdach, S. E G.

In: Bone Marrow Transplantation, Vol. 9, No. 1, 1992, p. 57-62.

Research output: Contribution to journalArticle

Dilloo, D, Hanenberg, H, Schneider, EM, Hauch, M, Nurnberger, W, Zimmer, BM, Vohringer, R, Wernet, P, Gobel, U & Burdach, SEG 1992, 'Treatment of donor T cell-mediated hematopoietic suppression after haploidentical bone marrow transplantation by T cell modulation in a patient with severe combined immunodeficiency', Bone Marrow Transplantation, vol. 9, no. 1, pp. 57-62.
Dilloo, D. ; Hanenberg, H. ; Schneider, E. M. ; Hauch, M. ; Nurnberger, W. ; Zimmer, B. M. ; Vohringer, R. ; Wernet, P. ; Gobel, U. ; Burdach, S. E G. / Treatment of donor T cell-mediated hematopoietic suppression after haploidentical bone marrow transplantation by T cell modulation in a patient with severe combined immunodeficiency. In: Bone Marrow Transplantation. 1992 ; Vol. 9, No. 1. pp. 57-62.
@article{268bf1f7a64942caa5aa8e4fa5dc7c62,
title = "Treatment of donor T cell-mediated hematopoietic suppression after haploidentical bone marrow transplantation by T cell modulation in a patient with severe combined immunodeficiency",
abstract = "An 8-month-old male patient with severe combined immunodeficiency syndrome was transplanted with maternal, haploidentical T cell-depleted bone marrow without prior conditioning therapy. Acute graft-versus-host disease developed 2 weeks post bone marrow transplantation (BMT) and as successfully treated with cortisone. After cortisone withdrawal the patient developed myeloid and B cell depression concomitant with T cell activation. For specific T cell modulation, treatment with the T cell receptor (TCR) αβ chain-binding MoAb BMA031 as initiated in combination with cyclosporin A. GM-CSF as given to enhance myeloid reconstitution. About 1 year post BMT, B cell and granulocyte counts were within the normal range with stable chimerism in both lineages. B cell proliferation tests were normal and first signs of in vitro immunoglobulin synthesis occurred.",
author = "D. Dilloo and H. Hanenberg and Schneider, {E. M.} and M. Hauch and W. Nurnberger and Zimmer, {B. M.} and R. Vohringer and P. Wernet and U. Gobel and Burdach, {S. E G}",
year = "1992",
language = "English",
volume = "9",
pages = "57--62",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Treatment of donor T cell-mediated hematopoietic suppression after haploidentical bone marrow transplantation by T cell modulation in a patient with severe combined immunodeficiency

AU - Dilloo, D.

AU - Hanenberg, H.

AU - Schneider, E. M.

AU - Hauch, M.

AU - Nurnberger, W.

AU - Zimmer, B. M.

AU - Vohringer, R.

AU - Wernet, P.

AU - Gobel, U.

AU - Burdach, S. E G

PY - 1992

Y1 - 1992

N2 - An 8-month-old male patient with severe combined immunodeficiency syndrome was transplanted with maternal, haploidentical T cell-depleted bone marrow without prior conditioning therapy. Acute graft-versus-host disease developed 2 weeks post bone marrow transplantation (BMT) and as successfully treated with cortisone. After cortisone withdrawal the patient developed myeloid and B cell depression concomitant with T cell activation. For specific T cell modulation, treatment with the T cell receptor (TCR) αβ chain-binding MoAb BMA031 as initiated in combination with cyclosporin A. GM-CSF as given to enhance myeloid reconstitution. About 1 year post BMT, B cell and granulocyte counts were within the normal range with stable chimerism in both lineages. B cell proliferation tests were normal and first signs of in vitro immunoglobulin synthesis occurred.

AB - An 8-month-old male patient with severe combined immunodeficiency syndrome was transplanted with maternal, haploidentical T cell-depleted bone marrow without prior conditioning therapy. Acute graft-versus-host disease developed 2 weeks post bone marrow transplantation (BMT) and as successfully treated with cortisone. After cortisone withdrawal the patient developed myeloid and B cell depression concomitant with T cell activation. For specific T cell modulation, treatment with the T cell receptor (TCR) αβ chain-binding MoAb BMA031 as initiated in combination with cyclosporin A. GM-CSF as given to enhance myeloid reconstitution. About 1 year post BMT, B cell and granulocyte counts were within the normal range with stable chimerism in both lineages. B cell proliferation tests were normal and first signs of in vitro immunoglobulin synthesis occurred.

UR - http://www.scopus.com/inward/record.url?scp=0026586501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026586501&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 57

EP - 62

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -